Research statistics

Pemvidutide research: publications and trials

What has been published on Pemvidutide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Pemvidutide works or is safe. For what it is and what the studies found, see the Pemvidutide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

14

Since 2011

Publications in 2026 so far

6

Through November 15, 2026

Human clinical research

35.7%

5 of 14 classified

Registered clinical trials

16

ClinicalTrials.gov

Randomized controlled trials

4

Publications reporting an RCT in people

Systematic reviews and meta-analyses

3

Preclinical studies

14.3%

1 animal · 0 in vitro · 1 computational

Records that only mention it

5

Not counted above

Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.

What to keep in mind

  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Pemvidutide publications by year and evidence

2011, Human clinical research: 1 of 12022, Preclinical (animal, in vitro, computational): 1 of 12024, Human clinical research: 1 of 22024, Reviews and meta-analyses: 1 of 22025, Human clinical research: 2 of 42025, Reviews and meta-analyses: 1 of 42025, Other and not yet classified: 1 of 42026 (to date), Human clinical research: 1 of 62026 (to date), Preclinical (animal, in vitro, computational): 1 of 62026 (to date), Reviews and meta-analyses: 4 of 6Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified024620112022202420252026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
201110001
202201001
202410102
202520114
2026 (to date)11406

Study types

Randomized controlled trial4
Review3
Meta-analysis2
Animal study1
Other clinical trial1
Computational study1
Editorial, letter or other1
Systematic review1

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health9
Gastrointestinal7
Obesity and weight management6
Endocrinology4
Cardiovascular2
Neurological and mental health1
Oncology1

Registered clinical trials

4 of 8 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 10 · Terminated: 3 · Active, not recruiting: 1 · Recruiting: 1 · Withdrawn: 1
Phase 1: 7 · Phase 1 / Phase 2: 4 · Phase 2: 4 · Phase 3: 1

TrialStatusPhaseStartedResults
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHNCT07795164 · 1,800 enrolledRecruitingPhase 32026-07—
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 · 121 enrolledActive, not recruitingPhase 22025-06—
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 · 100 enrolledCompletedPhase 22025-05—
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711 · 212 enrolledCompletedPhase 22023-07—
Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 · 391 enrolledCompletedPhase 22022-03—
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911 · 64 enrolledCompletedPhase 12022-03—
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)NCT05134662 · 55 enrolledCompletedPhase 12022-02—
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885 · 95 enrolledCompletedPhase 12021-09—
Pemvidutide (ALT-801) DDI Study in Healthy VolunteersNCT04972396 · 40 enrolledCompletedPhase 12021-09—
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityNCT04561245 · 100 enrolledCompletedPhase 12020-11—
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaNCT01670994 · 6 enrolledTerminatedPhase 1, Phase 22012-08Posted
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerNCT01625260 · 12 enrolledTerminatedPhase 1, Phase 22012-03Posted
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaNCT01478074WithdrawnPhase 12011-11—
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerNCT01326871 · 68 enrolledCompletedPhase 1, Phase 22011-09Posted
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic MelanomaNCT01029873 · 22 enrolledTerminatedPhase 1, Phase 22010-02Posted
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic MalignanciesNCT00496860 · 26 enrolledCompletedPhase 12007-05Posted

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.

    Digestive diseases (Basel, Switzerland) · November 9, 2026 · Meta-analysis · cited 0 times · open access

    PMID 43002386 · DOI 10.1159/ddi/acnag020 · Reviews and meta-analyses

  2. Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.

    Naunyn-Schmiedeberg's archives of pharmacology · March 25, 2026 · Meta-analysis · cited 0 times

    PMID 41879841 · DOI 10.1007/s00210-026-05257-1 · Reviews and meta-analyses

  3. Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.

    Addictive behaviors reports · January 30, 2026 · Systematic review · cited 6 times · open access

    PMID 41696398 · DOI 10.1016/j.abrep.2026.100671 · Reviews and meta-analyses

  4. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.

    The lancet. Gastroenterology & hepatology · November 11, 2026 · Randomized controlled trial · cited 0 times

    PMID 43014327 · DOI 10.1016/s2468-1253(26)00263-3 · Human clinical research

  5. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

    Lancet (London, England) · November 11, 2025 · Randomized controlled trial · cited 43 times

    PMID 41237796 · DOI 10.1016/s0140-6736(25)02114-2 · Human clinical research

  6. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

    JHEP reports : innovation in hepatology · June 18, 2025 · Randomized controlled trial · cited 14 times · open access

    PMID 41113119 · DOI 10.1016/j.jhepr.2025.101483 · Human clinical research

  7. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.

    Journal of hepatology · July 11, 2024 · Randomized controlled trial · cited 178 times · open access

    PMID 39002641 · DOI 10.1016/j.jhep.2024.07.006 · Human clinical research

  8. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.

    Clinical cancer research : an official journal of the American Association for Cancer Research · October 12, 2011 · Other clinical trial · cited 54 times · open access

    PMID 21994418 · DOI 10.1158/1078-0432.ccr-11-1817 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.

    Journal of hepatology · July 11, 2024 · Randomized controlled trial · cited 178 times · open access

    PMID 39002641 · DOI 10.1016/j.jhep.2024.07.006 · Human clinical research

  2. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.

    Clinical cancer research : an official journal of the American Association for Cancer Research · October 12, 2011 · Other clinical trial · cited 54 times · open access

    PMID 21994418 · DOI 10.1158/1078-0432.ccr-11-1817 · Human clinical research

  3. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.

    Scientific reports · April 23, 2022 · Animal study · cited 52 times · open access

    PMID 35461369 · DOI 10.1038/s41598-022-10577-2 · Animal studies

  4. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

    Lancet (London, England) · November 11, 2025 · Randomized controlled trial · cited 43 times

    PMID 41237796 · DOI 10.1016/s0140-6736(25)02114-2 · Human clinical research

  5. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.

    Indian journal of endocrinology and metabolism · September 4, 2024 · Review · cited 17 times · open access

    PMID 39676791 · DOI 10.4103/ijem.ijem_442_23 · Reviews and meta-analyses

Latest publications

  1. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.

    The lancet. Gastroenterology & hepatology · November 11, 2026 · Randomized controlled trial · cited 0 times

    PMID 43014327 · DOI 10.1016/s2468-1253(26)00263-3 · Human clinical research

  2. GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.

    Digestive diseases (Basel, Switzerland) · November 9, 2026 · Meta-analysis · cited 0 times · open access

    PMID 43002386 · DOI 10.1159/ddi/acnag020 · Reviews and meta-analyses

  3. Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.

    Cureus · June 29, 2026 · Review · cited 0 times · open access

    PMID 42529769 · DOI 10.7759/cureus.111728 · Reviews and meta-analyses

  4. Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.

    Naunyn-Schmiedeberg's archives of pharmacology · March 25, 2026 · Meta-analysis · cited 0 times

    PMID 41879841 · DOI 10.1007/s00210-026-05257-1 · Reviews and meta-analyses

  5. Systemic Pharmacokinetic Principles of Therapeutic Peptides.

    Clinical pharmacokinetics · February 9, 2026 · Computational study · cited 3 times · open access

    PMID 41661442 · DOI 10.1007/s40262-025-01615-z · Computational studies

  6. Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.

    Addictive behaviors reports · January 30, 2026 · Systematic review · cited 6 times · open access

    PMID 41696398 · DOI 10.1016/j.abrep.2026.100671 · Reviews and meta-analyses

  7. The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.

    Lancet (London, England) · December 1, 2025 · Editorial, letter or other · cited 2 times

    PMID 41352959 · DOI 10.1016/s0140-6736(25)02304-9 · Commentary and other

  8. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

    Lancet (London, England) · November 11, 2025 · Randomized controlled trial · cited 43 times

    PMID 41237796 · DOI 10.1016/s0140-6736(25)02114-2 · Human clinical research

  9. Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.

    Drugs in context · July 24, 2025 · Review · cited 2 times · open access

    PMID 40734920 · DOI 10.7573/dic.2025-4-8 · Reviews and meta-analyses

  10. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

    JHEP reports : innovation in hepatology · June 18, 2025 · Randomized controlled trial · cited 14 times · open access

    PMID 41113119 · DOI 10.1016/j.jhepr.2025.101483 · Human clinical research

Browse all 14 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: ALT-801; Pemvidutide

((TITLE_ABS:"ALT-801" OR CHEM:"ALT-801" OR TITLE_ABS:"ALT801" OR CHEM:"ALT801") OR (TITLE_ABS:"Pemvidutide" OR CHEM:"Pemvidutide")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Pemvidutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/pemvidutide